期刊文献+

巨块型宫颈癌术前介入化疗及预后相关因素分析 被引量:1

Chemoresistance-related factors for preoperative interventional chemotherapy and prognosis in bulky cervical cancer
下载PDF
导出
摘要 目的 探讨巨块型宫颈癌术前化疗敏感相关因素及预后价值。方法 回顾性分析 6 8例巨块型宫颈癌或桶状宫颈 (肿瘤直径≥ 4cm) ,治疗方法为术前介入化疗 2个疗程后行广泛性全子宫切除加盆腔淋巴结清扫术 ,2 1例病理检查发现有高危因素者术后补充放疗 ;采用免疫组化法检测治疗前肿瘤组织的MDR、GST л和PCNA的表达。统计采用SPSS 8.0软件。结果 MDR阳性率为 31% ,GST л阳性率为 5 1% ,PCNA指数 >5 0 %和≤ 5 0 %各有 38例和 30例。术前化疗总有效率为 84 %。化疗疗效与MDR表达及PCNA指数高低密切相关 ,MDR(- )组化疗有效率为 91% ,而MDR(+)组仅 6 7% (P =0 .0 13)。PCNA指数 >5 0 %组的化疗有效率明显高于≤ 5 0 %组 (P =0 .0 0 1)。GST л的表达与化疗疗效无明显相关。多因素分析发现 ,宫旁浸润与淋巴结转移是独立的预后因素 ;MDR(+)组生存率较MDR(- )组低 ,但两者无显著性差异。结论 MDR和PCNA可作为预示术前化疗有效的指标 ,为临床制订合理的个体化治疗方案提供参考 ;宫旁浸润与淋巴结转移可预示预后 ;MDR与预后也相关。 Objective To identify the chemoresistant factors predicting the response to preoperative chemotherapy and clinicopathological prognosis in bulky cervical cancer. Methods 68 patients with bulky cervical carcinoma treated with two courses of intraarterial infusion of cisplatin 80mg, 5 fluorouracil(5Fu) 1500mg and AT 1258 or EADR 60mg, followed by radical hysterectomy and pelvic lymphnodenectomy at our hospital between 1996-1999 were retrospectively reviewed. Expressions of the chemoresistance related proteins, such as P glycoprotein glutathione S transferase л(GST л), and proliferating cell nuclear antigen(PCNA) in the tumor cells were examined by immunohistochemistry in previous biopsy specimens. These results were compared with the chemotherapeutic response obtained by gynecological examination and vagina ultrasonic. 68 patients were followed up. SPSS 8.0 was used. Results P glycoprotein expression rate was 31% and GST л expressioin rate was 51%. There were 38 patients whose PCNA labellings were more than 50% and 30 less than 50%. The total chemotherapeutic response rate was 84%. Chemotherapeutic response rate was significantly correlated with P glycoprotein expression( P =0.013) and PCNA labelling ( P =0.001), but not GST л expression in the tumor cells. Parautrial involvement and lymph node metastasis were independent factors for prognosis in this group. The survival rate in MDR(+) group was lower than MDR(-) group. No significant correlation between eigher the expression of GST л or PCNA. Conclusions The expression of P glycoprotein and PCNA is potentially useful for predicting the response to preoperative chemotherapy for cervical cancer. The parautrial involvement and lymph node metastasis were independent prognostic factors for the survival rate including. the expression of P glycoprotein.
出处 《介入放射学杂志》 CSCD 2002年第6期427-430,共4页 Journal of Interventional Radiology
关键词 化疗敏感性 术前介入化疗 巨块型宫颈癌 Response/chemoresistance Preoperation interventional chemotherapy Cervical cancer/bulky
  • 相关文献

参考文献10

  • 1Minagawa Y, Kigawa J, Lrie T, et al. Radical surgery following neoadjuvant chemotherapy for patients with cervical cancer. Ann Surg Oncol,1998,5:539-533.
  • 2Sugiyama T, Takashi N, Yasuyuki H, et al. Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer. Gynecol Oncol, 1998,69:130-136.
  • 3Sananes C, Giaroli A, Soderini A, et al. Neoadjuvant chemotherapy followed by radical hysterectomy and postoperative adjuvant radiotherapy in the treatment of carcinoma of the cervix uteri: long-term follow-up of a pilot study. Eur J Gynecol Oncol, 1998,19:368-373.
  • 4Kohishi I, Nanbu K, Mandai M, et al. Tumor response to neoadjuvant chemotherapy correlates with the expression of P-glycoprotein and PCNA but not GST-л in the tumor cells of cervical carcinoma. Gynecol Oncol, 1998,70:365-371.
  • 5王华英,蔡树模,孙敏,张玉勤.介入化疗联合根治术治疗局部晚期宫颈癌的疗效[J].上海医科大学学报,2000,27(3):218-221. 被引量:25
  • 6Rose PG. Locally advanced cervical cancer. Curr Opin Obstet Gynecol,2001,13,65-70.
  • 7Panici PB, Maneschi F, Scambia G, et al. Lymphatic spread of cervical cancer: an anatomical and pathological study based on 225 radical hysterectomies with systematic pelvic and aortic lymphadenectomy. Gynecol Oncol, 1996,62:19-24.
  • 8张志毅.20年来手术治疗子宫颈癌的经验[J].中华妇产科杂志,1987,22:9-9.
  • 9Finan MA, DeCesare S, Fiorica JV, et al: Radical hysterectomy for stage IB1 vs IB2 carcinoma of the cervix: does the new staging system predict morbidity and survival? Gynecol Oncol, 1996,62,139-147.
  • 10Peters Ⅲ WA, Liu PY, Barrett RJ, et al. Cisplatin and 5-fluorouracil plus radiation therapy are superior to radiation therapy as adjunctive in high-risk early stage carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: report of a phase Ⅲ intergroup study. J Clin Oncol, 2000,18,1606-1613.

二级参考文献7

  • 1[1]Petterson F.Annual report on the results of treatment in gynecological cancer,stockholm.FIGO,1992,21:38-40
  • 2[2]Minagawa Y,Kigawa J,lrie T,et al.Radical surgery following neoadjuvant chemotherapy for patients with stage ⅢB cervical cancer.Ann Surg Oncol,1998,5(6):539-543
  • 3[3]Sugiyama T,Takashi N,Yasuyuki H,et al.Neoadjuvant intrarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advvanced cervical cancer.Gynecol Oncol,1998,69:130-136
  • 4[4]Sananes C,Giaroli A,Soderini A,et al.Neoadjuvant chemotherapy followed by radical hysterectomy and postoperative adjuvant chemotherapy in the treatment of carcinoma of the cervix uteri:long-term follow-up of a pilot study.Eur J Gynaecol Oncol,1998,19(4):368-373
  • 5[5]Seldinger Sl.Catheter replacement of needle in percutaneous arteriography:New technique.Acta Radiol,1953,39:368-370
  • 6[6]Cohen CJ,Deppe G,Castro-Marin CA,et al.Treatment of advanced squamous cell cancer of the cervix with cis-platinum (ll) diammine dichloride (CNSC119875).Amer J Obstet Gynecol,1978,130:853-854
  • 7[7]Panici PB,Maneschi F,Scambia G,et al.Lymphatic spread of cervical cancer:an anatomical and pathological study based on 225 radical hysterectomies with systematic pelvic and aortic lymphadenectomy.Gynecol Oncol,1996,62:19-24

共引文献25

同被引文献11

  • 1Kumar JV, Doval DC, Rao R, et al. A retrospective study of patients with locally advanced cancer of the cervix treated with neoadjuvant chemotherapy followed by radical surgery [ J ]. Int J Gynecol Cancer, 2009,19 (3) :417 - 422.
  • 2Glynne - Jones R, Hoskin P. Neoadjuvant Cisplatin chemo- therapy before chemoradiation: a flawed paradigm [ J ]. J Clin 0ncol,2007,25 (33) : 5281 - 5286.
  • 3Jobo T. Outpatient chemotherapy in gynecologic oncology [ J ]. Gan To Kagaku Ryoho,2006,33 (2) :369 - 371.
  • 4Ferrandina G, Legge F, Fagotti A, et al. Preoperative con- comitant chemoradiotherapy in locally advanced cervical cancer: safety, outcome, and prognostic measures [ J ]. Gyne- col Oncol,2007,107( 1 ) :127 - 132.
  • 5Zand B, Euscher ED, Soliman PT, et al. Rate of para - aortic lymph node micrometastasis in patients with locally ad-vanced cervical cancer [ J ]. Gynecol Oncol, 2010,119 ( 3 ) : 422 - 425.
  • 6Mangioni C, Landoni F, Colombo A, et al. Concurrent plati- num - based chemo - and radiotherapy for locally advanced cervical cancer: a new gold - standard treatment [ J ]. Ann 0nco1,1999,10(6) :647 -648.
  • 7Desoize B, Madoulet C. Particular aspects of platinum com- pounds used at present in cancer treatment [ J ]. Crit Rev Oncol Hematol,2002,42 (3) :317 - 325.
  • 8Koshiyama M, Kinezaki M, Uchida T, et al. Chemosensitivi- ty testing of a novel platinum analog, nedaplatin ( 254 - S) ,in human gynecological carcinomas:a comparison with cisplatin [ J ]. Anticaneer Res ,2005 ,25 (6c) :4499 - 4502.
  • 9Furuse K, Fukuoka M, Asamoto H, et al. A randomized comparative study of 254- S plus vindesine(VDS) vs. cis- platin(CDDP) plus VDS in patients with advanced non- small cell lung cancer(NSCLC) [ J]. Gan To Kagaku Ryo- ho, 1992,19 (7) : 1019 - 1026.
  • 10魏毅利,方建玲.局部晚期宫颈癌综合治疗方法探讨[J].实用肿瘤学杂志,2008,22(3):224-228. 被引量:11

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部